机器学习模型的开发,验证和临床应用,用于风险分层和宫癌查的管理,基于全基因定型HRHPV测试 (SMART-HPV):一个建模研究
Binhua Dong1,2, Zhen Lu3, Tianjie Yang4
1Department of Gynecology, Fujian Key Laboratory of Women and Children's Critical Diseases Research, Fujian Maternity and Child Health Hospital, College of Clinical Medicine for Obstetrics & Gynecology and Pediatrics, Fujian Medical University, Fuzhou, Fujian, China.
The Lancet regional health. Western Pacific
|February 10, 2025
概括
使用高风险人类乳头瘤病毒 (hrHPV) 完整基因定型的新型宫癌预测模型可以有效指导结肠镜转诊,特别是在查率低的地区. 这个工具有助于风险分层,以更好地预防宫癌.
科学领域:
- 在瘤学瘤学.
- 遗传学 是一个遗传学.
- 机器学习 机器学习
背景情况:
- 高风险人类乳头瘤病毒 (hrHPV) 完整的基因型鉴定对于宫癌查中的风险分层至关重要.
- 现有的查方法需要加强,特别是在查参与率低的地区.
- 开发预测模型可以优化镜推,提高查效率.
研究的目的:
- 开发和验证使用hrHPV完整基因定型数据的宫癌预测模型.
- 在宫癌查率较低的环境中有效指导镜转诊.
- 为了比较用于宫癌预测的机器学习模型的性能.
主要方法:
- 开发并比较了四种机器学习模型:XGBoost,SVM,RF和NB.
- 利用了来自全国宫癌查项目的数据,涉及599,043名女性.
- 使用AUROC,AUPRC,精度,布里尔得分,校准曲线和DCA评估模型性能.
主要成果:
- 简化临床风险预测模型包括hrHPV,基因型计数,细胞学,HPV16,HPV18,年龄,HPV52,HPV39和妇科检查.
- 最优的XGBoost模型展示了强大的区分 (最大AUROC0.989) 和校准,用于在五个外部验证集中预测CIN2+.
- 决策曲线分析表明,当临床决策值概率低于0.80.8时,XGBoost模型的净益优越.
结论:
- 一个新的宫癌风险预测模型是使用hrHPV完整基因型和基本临床数据开发的.
- 这种预测工具可以实现风险分层和优化结肠镜推,特别有利于低查设置.
- 该模型显示了提高宫癌查效率和患者管理的巨大潜力.
相关概念视频
01:12Hazard Ratio
78
The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial...
For example, in a clinical trial...
78
01:21Cancer Survival Analysis
321
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
321